search

Active clinical trials for "Squamous Cell Carcinoma of Head and Neck"

Results 271-280 of 1255

Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell CarcinomaRadiotherapy2 more

This study is looking to see if sintilimab, an anti-PD-1 McAb given with cisplatinum and paclitaxel (2 chemotherapy agents) during induction therapy in advanced head and neck squamous cell carcinoma can significantly shrink the subject's cancer, then de-escalation radiotherapy can be used.

Recruiting29 enrollment criteria

Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

Malignant Neoplasms of Respiratory and Intrathoracic OrgansSquamous Cell Carcinoma of the Larynx

To find the highest tolerable dose of stereotactic hypofractionated radioablation (HYDRA) radiation that can be given to patients with laryngeal cancer. The safety of this radiation will also be studied.

Recruiting18 enrollment criteria

Post-Operative Radiotherapy De-Escalation of Negative Nodal Regions in Head and Neck Squamous Cell...

Head and Neck Carcinoma

This is a non-randomized prospective trial evaluating the non- inferiority of de-escalating the volume and/or dose of elective nodal irradiation in post-operative head and neck squamous cell carcinomas.

Recruiting15 enrollment criteria

A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell...

CarcinomaSquamous Cell

The purpose of this study is to determine whether cervical lymph node dissection is necessarily performed in the presence of early-stage oral squamous cell carcinoma.

Recruiting14 enrollment criteria

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Any Solid Tumors Progressed After a Prior ImmunotherapyCervical Cancer14 more

This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

Recruiting32 enrollment criteria

Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation...

Head and Neck Cancer

The goal of this randomized treatment study is to formally compare quality of life in patients with at least one pN0 hemi-neck after resection of a squamous cell carcinoma of the oral cavity treated with a primary radiation therapy versus a secondary targeted radiation therapy approach, to provide a high level of evidence to guide the selection of treatment options.

Recruiting15 enrollment criteria

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M HNSCC

Head and Neck Squamous Cell Carcinoma

Camrelizumab is an antibody targeting programmed death receptor 1 (PD-1) and its ligand programmed death-ligand 1 (PD- L1) that is designed to boost the immune system. It does this by allowing immune cells to fight the cancer. Camrelizumab has been approved by China's National Medical Products Administration (NMPA) for the treatment of esophageal cancer, liver cancer and lung cancer. It is currently under study for the treatment of head and neck squamous cell cancer.

Recruiting36 enrollment criteria

Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients...

Head and Neck Squamous Cell Carcinoma

To investigate weather concurrent JS001 with postoperative radiotherapy would have survival benefit in intermediate/high Risk HNSCC Patients who cannot take cisplatin

Recruiting16 enrollment criteria

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Squamous Cell Carcinoma of Head and Neck

This study is being done because both 5-azacytidine and nivolumab can influence the immune system's response to HPV-associated head and neck cancer, and we wish to evaluate whether taking 5-azacytidine will make HPV-associated head and neck cancer more sensitive to treatment with nivolumab. 5-Azacytidine (5-AZA) is a chemotherapy, and nivolumab is an immunotherapy. Both drugs are approved for use in the US by the Food and Drug Administration (FDA) for use in the treatment of different types of cancer, and nivolumab is approved for use in head and neck cancer that has previously been treated with chemotherapy. Because they are not approved to be used together in HPV-associated head and neck cancer, these drugs are considered experimental in this study. For this study, the drugs will be used either together or separately.

Recruiting21 enrollment criteria

The SWOAR Trial Sparing of Swallowing and Aspiration Related Organs at Risk & Submandibular Gland...

Head and Neck NeoplasmsSwallowing Sparing IMRT

The aim of SWOAR TRIAL is to test sparing of Dysphagia/ Aspiration risk structures (DARS) and contra lateral submandibular gland by IMRT. HNSCC of the oropharynx, larynx and the hypopharynx treated with radical concurrent chemoradiotherapy or radiotherapy will be included in the trial. Patients will be randomized to SWOAR IMRT or standard IMRT. Swallowing function will be evaluated the MD Anderson Dysphagia Inventory (MDADI) scoring. Difference in the mean composite score of MDADI, a patient-reported outcome, at 6 months post radiotherapy is the primary outcome of the trial. Secondary Objectives include longitudinal assessment of aspiration prevention as evaluated by FEES by the 8 point penetration-aspiration score. Swallowing function, will be assessed by using the MDADI at baseline, at completion of CRT/RT, 3, 6, 12, and 24 months. Assessment of acute and late toxicity assessed at baseline, weekly during radiotherapy and then at 3, 6, 12, and 24 months post treatment as per RTOG and LENT SOMA score, respectively. Treatment outcomes will be assessed in terms of loco-regional tumor recurrence and overall survival, assessed at follow-up visits 3, 6, 12, and 24 months post treatment and then annually until 5 years post treatment.

Recruiting20 enrollment criteria
1...272829...126

Need Help? Contact our team!


We'll reach out to this number within 24 hrs